GABRP

GABRP, the GABAA receptor π subunit, functions as a membrane-associated driver of malignant cell behavior across multiple non-neuronal cancers, acting through both GABA-independent and GABA-dependent mechanisms (PMID:30826748, PMID:25012653). In pancreatic cancer it physically associates with the calcium-activated potassium channel KCNN4 to trigger Ca2+ entry independent of GABA neurotransmitter signaling, activating NF-κB to induce CXCL5 and CCL20 expression that recruits macrophages and promotes tumor progression (PMID:30826748). A second, recurrent mechanism is activation of MEK/ERK signaling: GABRP sustains ERK1/2 phosphorylation to drive migration, invasion, and EMT in basal-like breast, ovarian, and pancreatic cancer cells, with pharmacological MEK/ERK inhibition phenocopying GABRP loss in each setting (PMID:25012653, PMID:28524180, PMID:37326897). In triple-negative breast cancer stem cells GABRP interacts with EGFR to sustain EGFR signaling, maintaining stemness and conferring resistance to paclitaxel, doxorubicin, and cisplatin (PMID:34023418). GABRP expression is itself controlled by promoter DNA methylation (PMID:28524180) and by upstream regulators including miR-320c and CD44s (PMID:32964961, PMID:35846884). Beyond cancer, GABRP mediates GABA signaling required for airway Club cell proliferation and differentiation into goblet cells (PMID:34007329). No structural or reconstituted biochemical mechanism for these interactions has been characterized in the available corpus.

1. 2014 Medium

   Established that GABRP drives a malignant phenotype through intracellular kinase signaling rather than canonical neurotransmission, linking it to ERK1/2 activation and basal-like cytokeratin expression in breast cancer.

   Evidence Stable shRNA knockdown in two BLBC cell lines with phospho-ERK1/2 western blot, selective ERK1/2 inhibitor phenocopy, and migration assays

   PMID:25012653

   Open questions at the time

   • No reconstitution or direct demonstration of how GABRP couples to ERK1/2
   • Single lab, no in vivo validation
   • Mechanism of ERK activation upstream of phosphorylation undefined
2. 2017 Medium

   Generalized the GABRP–MAPK/ERK axis to ovarian cancer and identified promoter DNA methylation as a control mechanism for GABRP expression.

   Evidence Knockdown and overexpression in SK-OV-3 cells with MEK inhibitor U0126 phenocopy, migration/invasion assays, and genome-wide methylation profiling

   PMID:28524180

   Open questions at the time

   • No biochemical link between GABRP and the MEK/ERK cascade
   • Single cell line for functional readouts
   • Causal demonstration that -963 CpG methylation governs phenotype not shown
3. 2019 High

   Defined a GABA-independent mechanism in which GABRP physically partners with KCNN4 to drive Ca2+/NF-κB signaling and remodel the tumor immune microenvironment, distinguishing it from classical receptor function.

   Evidence Reciprocal Co-IP and proximity ligation assay, electrophysiology, promoter luciferase, ELISA, and xenograft/orthotopic models with macrophage depletion

   PMID:30826748

   Open questions at the time

   • Structural basis of GABRP-KCNN4 interaction unresolved
   • How GABRP gates Ca2+ entry mechanistically not defined
   • Relationship between this Ca2+/NF-κB axis and the ERK axis seen elsewhere unaddressed
4. 2020 Low

   Placed GABRP within a regulatory network as a functional downstream target of miR-320c controlling cervical cancer cell migration.

   Evidence miR-320c overexpression with GABRP rescue and migration assays in HeLa and C33-A cells

   PMID:32964961

   Open questions at the time

   • No direct 3'UTR reporter validation of targeting described
   • Single lab
   • Downstream effector mechanism of GABRP in cervical cancer not examined
5. 2021 Medium

   Identified EGFR as a physical partner of GABRP in TNBC stem cells, connecting GABRP to stemness maintenance and chemoresistance.

   Evidence Co-IP for GABRP-EGFR interaction, knockdown/overexpression, stemness and drug-sensitivity assays, and EGFR-pathway western blots

   PMID:34023418

   Open questions at the time

   • Co-IP without reciprocal or structural confirmation
   • Mechanism by which GABRP sustains EGFR expression unknown
   • Single lab
6. 2021 Low

   Demonstrated a non-malignant, GABA-dependent role for GABRP in airway epithelial Club cell proliferation and differentiation into goblet cells.

   Evidence Naphthalene injury model and organoid cultures with GABRP antagonist bicuculline methiodide, RT-qPCR for goblet markers

   PMID:34007329

   Open questions at the time

   • Pharmacological blockade only; no genetic loss-of-function
   • Single method per conclusion
   • Downstream signaling mediating differentiation not defined
7. 2022 Low

   Positioned GABRP downstream of CD44s in pancreatic cancer chemoresistance, extending its regulatory inputs.

   Evidence shRNA CD44 knockdown and CD44s overexpression with viability/colony assays and RT-qPCR/western blot in pancreatic cancer lines

   PMID:35846884

   Open questions at the time

   • No direct GABRP rescue to confirm epistasis
   • Pathway placement is indirect
   • Single lab
8. 2023 Medium

   Confirmed the GABRP–MEK/ERK axis drives invasion, EMT, and tumor growth in pancreatic cancer, consolidating MAPK signaling as a recurrent GABRP effector across tumor types.

   Evidence Bidirectional knockdown/overexpression with Transwell assays, MEK/ERK western blots, pharmacological inhibitor rescue, and xenograft growth assay

   PMID:37326897

   Open questions at the time

   • No biochemical mechanism coupling GABRP to MEK/ERK
   • Relationship to the GABRP-KCNN4/Ca2+ axis in the same tissue unclear
   • Single lab

• How GABRP, a GABAA receptor subunit, mechanistically couples to its partner channels and receptors (KCNN4, EGFR) and to the MEK/ERK cascade in the absence of canonical GABA gating remains unresolved.
• No structural model of GABRP complexes
• No reconstituted biochemical assay of GABRP signaling
• Whether a single unified mechanism underlies the Ca2+, ERK, and EGFR phenotypes is unknown